Axsome Therapeutics (AXSM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today is joining the global community of mental health advocates, including Mental Health America, during May’s Mental Health Month to raise awareness of the importance of mental health as a key element of overall health. Axsome is committed to the millions of individuals living wit

In this article, we will be taking a look at the 15 most black states in the US. If you do not want to learn about the demographics of global black population, head straight to the 5 Most Black States in the US. Overview of the Global Black Population: Demographics, Trends, and Immigration Patterns The […]

AXS-05 in Alzheimer’s disease agitation data featured in oral plenary session New data for AXS-07 in migraine demonstrating efficacy in pooled analysis Presentations on cognitive and wake promoting effects of solriamfetol NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced presentations highlighting its innovative p

NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced it will report its financial results for the first quarter of 2024 on Monday, May 6, 2024, before the opening of the U.S. financial markets. Axsome’s management team will host a conference call at 8:00 a.m. Eastern Time on May 6, 2024, to discuss these results and

Axsome's (AXSM) phase III ENGAGE study is set to evaluate the efficacy and safety of solriamfetol for the treatment of binge eating disorder in adults.

Axsome Therapeutics Inc (NASDAQ:AXSM), a biopharmaceutical company focused on developing novel therapies for the management of central nervous system (CNS) disorders, has reported an insider sell according to a recent SEC filing.

NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, announced the initiation of the ENGAGE Phase 3 trial of solriamfetol, an investigational treatment for binge eating disorder (BED) in adults. ENGAGE (Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol) is a Phase 3, randomized, double-blin

Biotech has seen its fair share of ups and downs, including a massive surge during the pandemic followed by a considerable dip. However, the industry will never go too far away from center stage as diseases and conditions will always need medicine and technology to treat them. These three strong buy biotech stocks are joining the upper ranks of their industry with promising new drugs and encouraging financials that justify serious consideration. Given the timeline of clinical trials and new rele

In this article, we will be taking a look at the 30 countries with the lowest depression rates. If you do not want to learn about the global depression treatment market, head straight to the 5 Countries with the Lowest Depression Rates. In countries with the lowest depression rates, individuals experience lower prevalence rates of […]